MasoompourSM, AnushiravaniA, NorouzAT. Evaluation of the effect of nebulized N-acetylcysteine on respiratory secretions in mechanically ventilated patients: Randomized clinical trial. Iran J Med Sci, 2015; 40(4):309–315.
2.
YounessHA, MathewsK, ElyaMK, et al.Dornase alpha compared to hypertonic saline for lung atelectasis in critically ill patients. J Aerosol Med Pulm Drug Deliv, 2012; 25(6):342–348; doi: 10.1089/jamp.2011.0954
3.
DonaldsonSH, BennettWD, ZemanKL, et al.Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med, 2006; 354(3):241–250; doi: 10.1056/NEJMoa043891
4.
BennettWD, BurbankA, AlmondM, et al.Acute and durable effect of inhaled hypertonic saline on mucociliary clearance in adult asthma. ERJ Open Res, 2021; 7(2); doi: 10.1183/23120541.00062-2021
5.
Herrero-CortinaB, AlcarazV, VilaróJ, et al.Impact of hypertonic saline solutions on sputum expectoration and their safety profile in patients with bronchiectasis: A randomized crossover trial. J Aerosol Med Pulm Drug Deliv, 2018; 31(5):281–289; doi: 10.1089/jamp.2017.1443
6.
SharafkhahM, AbdolrazaghnejadA, ZarinfarN, et al.Safety and efficacy of N-acetyl-cysteine for prophylaxis of ventilator-associated pneumonia: a randomized, double blind, placebo-controlled clinical trial. Med Gas Res, 2018; 8(1):19–23; doi: 10.1183/23120541.00062-2021
7.
Van MeenenDM, Van Der HoevenSM, BinnekadeJM, et al.Effect of on-demand vs routine nebulization of acetylcysteine with salbutamol on ventilator-free days in intensive care unit patients receiving invasive ventilation: a randomized clinical trial. Jama, 2018; 319(10):993–1001; doi: 10.1001/jama.2018.0949
8.
SheinSL, GallagherJT, DeakinsKM, et al.Prophylactic use of nebulized hypertonic saline in mechanically ventilated children: a randomized blinded pilot study. Respir Care, 2016; 61(5):586–592; doi: 10.4187/respcare.04418
9.
TruwitJD, FlemingK, NanchalRS. Empowering respiratory therapists to restrict nebulized 3% saline and N-acetylcysteine during mechanical ventilation. Respir Care, 2025; 70(8):937–945; doi: 10.1089/respcare.12586
10.
FlemingK, GeorgeJL, BazelakSJ, et al.Optimizing respiratory therapy resources by de-implementing low-value care. Respir Care, 2023; 68(5):559–564; doi: 10.4187/respcare.10712
11.
StricklandSL, RubinBK, HaasCF, et al.AARC clinical practice guideline: effectiveness of pharmacologic airway clearance therapies in hospitalized patients. Respir Care, 2015; 60(7):1071–1077; doi: 10.4187/respcare.04165
12.
Walsh-BaileyC, TsaiE, TabakRG, et al.A scoping review of de-implementation frameworks and models. Implementation Sci, 2021; 16(1):1–18; doi: 10.1186/s13012-021-01173-5
13.
ChatburnRL, FordRM, KauffmanGW. Determining the value-efficiency of respiratory care. Respir Care, 2021; 66(12):1892–1897; doi: 10.4187/respcare.09100
